USPTO Examiner MCMILLIAN KARA RENITA - Art Unit 1623

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18888371SOLID PSILOCIN SALTSSeptember 2024April 2025Allow711NoNo
18663460INHIBITING MONOACYLGLYCEROL LIPASE (MAGL)May 2024November 2024Allow610NoNo
18594323TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORSMarch 2024April 2025Abandon1310NoNo
18431308POTENTIATION OF HELMINTH TREATMENTFebruary 2024April 2025Abandon1410NoNo
18403360STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMALJanuary 2024November 2024Allow1101NoNo
184025386-[4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024October 2024Allow1030NoNo
183984804-[4,4-BIS(4-BROMOPHENYL)-5-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDDecember 2023October 2024Allow1030NoNo
18515734TREATING PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHYNovember 2023October 2024Allow1110NoNo
18495012NICOTINE FORMULATIONOctober 2023November 2024Abandon1310NoNo
18481787COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITYOctober 2023November 2024Abandon1310NoNo
18376339INJECTABLE IBUPROFEN FORMULATIONOctober 2023May 2025Abandon2020NoNo
18474108IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDESSeptember 2023September 2024Allow1220YesNo
18457567METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORSAugust 2023November 2024Allow1510NoNo
18362028CCR2 RECEPTOR ANTAGONISTS AND USES THEREOFJuly 2023September 2024Allow1310NoNo
18349221ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTIONJuly 2023April 2025Allow2130NoNo
18325919ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISMay 2023August 2024Allow1420NoNo
18302713PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAMEApril 2023December 2024Abandon2020NoNo
18095877COMBINATION THERAPY WITH AN ANTITUMOR ALKALOIDJanuary 2023February 2025Abandon2520YesNo
18093774AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOFJanuary 2023October 2024Allow2120YesNo
18059806SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOFNovember 2022July 2024Allow2020NoNo
17989298COLLAGEN-BASED DEVICE HAVING ANTIFUNGAL PROPERTIESNovember 2022March 2025Abandon2820NoYes
18049508ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOFOctober 2022March 2025Allow2940YesNo
17950802METHODS OF TREATING OCULAR INFLAMMATORY DISEASESSeptember 2022November 2024Allow2630YesNo
17745126GPR40 AGONISTSMay 2022December 2024Allow3151NoNo
17713384Osteogenic agents and uses thereofApril 2022April 2025Allow3631NoNo
17683197Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory InfectionsFebruary 2022August 2024Allow3020NoNo
17579271NEXT GENERATION REMDESIVIR ANTIVIRALSJanuary 2022June 2025Allow4141NoNo
17513383PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOFOctober 2021February 2023Abandon1630NoYes
17605828DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOROctober 2021April 2025Abandon4101NoNo
17593877HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORSSeptember 2021January 2025Abandon4001NoNo
17598500METHOD OF PROTECTING FIELD CORN FROM DAMAGE BY A PLANT PATHOGENSeptember 2021January 2025Abandon4010NoNo
17438841SPECIFICALLY SUBSTITUTED 3-(2-HALOGEN-6-ALKYL-4-PROPINYLPHENYL)-3-PYRROLIN-2-ONES AND TO THE USE THEREOF AS HERBICIDESSeptember 2021February 2025Abandon4101NoNo
17438452COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUSSeptember 2021January 2025Abandon4010NoNo
17437236INHIBITION OF ADENOVIRUS WITH FILOCICLOVIRSeptember 2021April 2025Allow4320NoNo
17431470MULTIPHASIC CONTRACEPTIVE AND/OR HORMONE REPLACEMENT THERAPYAugust 2021May 2025Abandon4411NoNo
17428029TREATMENT AND PREVENTION OF INTESTINAL INFLAMMATORY DISEASES WITH A BILE ACID DERIVATIVEAugust 2021January 2025Abandon4110NoNo
17381857COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATIONJuly 2021June 2024Abandon3531NoNo
174196646-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOFJune 2021February 2025Abandon4301NoNo
17331366METHODS OF TREATING THROMBOSISMay 2021March 2025Allow4541YesNo
17289816TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINEApril 2021May 2025Abandon4941NoNo
17099531ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISNovember 2020November 2024Abandon4840YesNo
17014954CANNABINOID FORMULATIONS AND METHODS INCLUDING THE ANTIOXIDANT C60September 2020November 2024Abandon5040NoNo
16767886COMPOSITIONS AND METHODS FOR CHARACTERIZING CANCERMay 2020November 2024Abandon5440YesNo
16624549Stratification Of Acute Myeloid Leukaemia Patients For Sensitivity To Kinase Pathway Inhibitor TherapyDecember 2019December 2024Allow6041YesNo
16419892Method for activating AMPK and the use of AdenineMay 2019May 2025Abandon6040YesYes
16277871COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISFebruary 2019February 2020Allow1210NoNo
16309733PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF PAINDecember 2018January 2025Abandon6040YesYes
16065441COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIAJune 2018September 2024Allow6070YesYes
15732352Method for producing solid formulations with improved dissolution by annealing with an adjuvantOctober 2017September 2021Abandon4741NoNo
15727772COMPOSITIONS FOR TOPICAL TREATMENT OF MICROBIAL INFECTIONSOctober 2017September 2024Allow60100YesNo
15062499ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDSMarch 2016March 2025Abandon6060YesYes
14883720INHIBITORS OF BETA-SECRETASEOctober 2015November 2018Allow3721YesNo
14792375Na/K-ATPase Ligand and Uses Thereof in Wound HealingJuly 2015September 2016Allow1410YesNo
14734999COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASESJune 2015May 2018Allow3530YesYes
14342889PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOFMarch 2014June 2020Abandon6080YesYes
140103542-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological DisordersAugust 2013May 2015Allow2110NoNo
13965499PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISMAugust 2013June 2015Allow2230YesNo
13942245PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISMJuly 2013June 2015Allow2330YesNo
13986573Method for treament of neurologic dysfunctionMay 2013February 2016Allow6020NoNo
13642907COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENTNovember 2012September 2015Allow3430YesNo
13592235Stable Bortezomib FormulationsAugust 2012June 2015Allow3431YesNo
13592228Stable Bortezomib FormulationsAugust 2012April 2015Allow3130YesNo
13415067PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERSMarch 2012June 2012Allow300YesNo
13327226METHODS FOR IMPROVING COGNITIVE FUNCTIONDecember 2011November 2014Allow3521YesYes
13123496TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLSMay 2011March 2018Allow6041NoYes
13072568METHODS AND PRODUCTS FOR TREATMENT OF DISEASESMarch 2011September 2013Allow2911YesNo
13051102STABLE BORTEZOMIB FORMULATIONSMarch 2011February 2015Allow4741YesYes
13031393TREATMENT OF LENGTH DEPENDENT NEUROPATHYFebruary 2011October 2014Allow4421NoNo
12919416CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSESNovember 2010January 2014Allow4121YesNo
12600637NOVEL COMPOSITIONS COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR AND THEIR USE IN METHODS OF TREATMENTOctober 2010November 2012Allow3621YesNo
12063996Vector Delivery-Based MicrobicidesSeptember 2010August 2015Allow6041YesNo
12856414TIVOZANIB AND TEMSIROLIMUS IN COMBINATIONAugust 2010May 2011Allow920YesNo
12832558Substituted Phenyl(oxy/thio)alkanol DerivativesJuly 2010August 2015Allow6041YesNo
12813721Materials and Methods for Inhibiting Mamalian S-Nitrosoglutathione ReductaseJune 2010January 2015Allow5621YesNo
12682064METHODS OF TREATMENT OF OPIOID TOLERANCE, PHYSICAL DEPENDENCE, PAIN AND ADDICTION WITH INHIBITORS OF CERTAIN GROWTH FACTOR RECEPTORSApril 2010April 2013Allow3631YesNo
12680484AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASESMarch 2010February 2014Allow4621YesYes
12698116PHARMACEUTICAL CREAMS WITH REFINED OLEIC ACIDFebruary 2010January 2011Allow1130YesNo
12698039METHOD OF TREATING A MUCOSAL AND/OR DERMAL ASSOCIATED CONDITIONFebruary 2010January 2011Allow1230YesNo
12698011METHOD OF TREATING A DERMAL AND/OR MUCOSAL ASSOCIATED CONDITIONFebruary 2010January 2011Allow1230YesNo
12698096PHARMACEUTICAL CREAMS WITH REDUCED IMIQUIMOD IMPURITIESFebruary 2010December 2010Allow1130YesNo
12697415METHOD OF INDUCING INTERFERON BIOSYNTHESISFebruary 2010January 2011Allow1330YesNo
12698113REDUCTION OF IMIQUIMOD IMPURITIES IN PHARMACEUTICAL CREAMSFebruary 2010January 2011Allow1130YesNo
12697296METHOD OF INDUCING CYTOKINE BIOSYNTHESISJanuary 2010January 2011Allow1230YesNo
12657052METHOD FOR TREATMENT OF NEUROLOGIC DYSFUNCTIONJanuary 2010December 2012Allow3511YesNo
12645094SMALL MOLECULE INHIBITION OF INTRACELLULAR TRANSPORTDecember 2009April 2012Allow2801NoNo
12437679STABLE PHARMACEUTICAL FORMULATIONSMay 2009February 2012Allow3321NoYes
11887502PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGSJanuary 2009March 2012Allow5301NoNo
12158918Cleansing CompositionOctober 2008September 2015Allow6041YesNo
12201226NON-AQUEOUS PHARMACEUTICAL COMPOSITIONAugust 2008October 2014Allow6031YesNo
12094255ORGANIC SULFUR COMPOUNDS AND USE THEREOFMay 2008May 2011Allow3611NoNo
11557455TREATMENT OF LENGTH DEPENDENT NEUROPATHYNovember 2006May 2011Allow5521YesYes
11542010TREATMENT FOR PARKINSON'S DISEASE-COMBINATION HIGH DOSE SEROTONERGIC SYNAPTIC REUPTAKE INHIBITOR WITH PHOSPHODIESTERASE INHIBITOROctober 2006May 2014Allow6070YesYes
11535001METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGSSeptember 2006September 2010Allow4811YesNo
11457063"METHODS AND PRODUCTS FOR TREATMENT OF DISEASES"July 2006January 2014Allow6021NoYes
11412353METHODS OF AND COMPOSITIONS FOR REDUCING NEURONAL CELL DEATHApril 2006December 2010Allow5621NoNo
11369638TOPICAL ANTIPSYCHOTIC COMPOSITIONMarch 2006August 2010Allow5321YesNo
11026198METHODS FOR IMPROVING THE AESTHETIC APPEARANCE OF SKINDecember 2004August 2010Allow6021NoYes
10992878METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERSNovember 2004November 2009Allow6011YesNo
10988337PHARMACOLOGICAL USES OF AZETIDINE DERIVATIVESNovember 2004February 2010Allow6021YesNo
10823365TOPICAL ANESTHETIC/OPIOID FORMULATIONS AND USES THEREOFApril 2004June 2010Allow6062YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCMILLIAN, KARA RENITA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
9
(90.0%)
Examiner Reversed
1
(10.0%)
Reversal Percentile
21.7%
Lower than average

What This Means

With a 10.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
25
Allowed After Appeal Filing
7
(28.0%)
Not Allowed After Appeal Filing
18
(72.0%)
Filing Benefit Percentile
38.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCMILLIAN, KARA RENITA - Prosecution Strategy Guide

Executive Summary

Examiner MCMILLIAN, KARA RENITA works in Art Unit 1623 and has examined 95 patent applications in our dataset. With an allowance rate of 73.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner MCMILLIAN, KARA RENITA's allowance rate of 73.7% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MCMILLIAN, KARA RENITA receive 2.71 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCMILLIAN, KARA RENITA is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +29.6% benefit to allowance rate for applications examined by MCMILLIAN, KARA RENITA. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.6% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 56.5% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 33.3% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.2% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.